Salmonella Typhi: A Review of Antibiogram Journey in Developing Countries


Citar

Texto integral

Resumo

Background: Typhoid fever poses a significant health challenge in low- and middleincome countries (LMiCs), impacting millions of individuals across various age groups. Its prevalence is particularly pronounced in South Asia. Factors contributing to its transmission in South Asia include rapid unplanned urbanization, urban-rural disparities, provision of poor water and sanitation facilities, and open defecation. The mortality rate of typhoid fever is up to 1%, and those who survive have a protracted period of poor health and carry an enormous financial burden. The treatment is further complicated by the emerging antibiotic resistance leaving few treatment options in hands. This issue has become more urgent due to the further emergence of extended drug-resistant (XDR) and multidrugresistant (MDR) typhoid strains, as well as their subsequent global spread. Fluoroquinoloneresistant Salmonella spp. is currently classified by the World Health Organization (WHO) as a high (Priority 2) pathogen. As a result, establishing minimum inhibitory concentrations (MIC) according to the latest guidelines may prove effective in treating typhoid fever and minimizing the rising threat of drug resistance.

Sobre autores

Lipika Singhal

Department of Microbiology, Government Medical College & Hospital

Email: info@benthamscience.net

Diljot Sandhu

Department of Microbiology, Government Medical College & Hospital

Email: info@benthamscience.net

Varsha Gupta

Department of Microbiology, Government Medical College & Hospital

Email: info@benthamscience.net

Ivneet Kour

Department of Microbiology, Government Medical College & Hospital

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Singhal L, Gupta PK, Kale P, Gautam V, Ray P. Trends in antimicrobial susceptibility of salmonella typhi from North India (2001-2012). Indian J Med Microbiol 2014; 32(2): 149-52. doi: 10.4103/0255-0857.129799 PMID: 24713900
  2. Antillón M, Warren JL, Crawford FW, et al. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. PLoS Negl Trop Dis 2017; 11(2): e0005376. doi: 10.1371/journal.pntd.0005376 PMID: 28241011
  3. Rasul F, Sughra K, Mushtaq A. Nadia Zeeshan, Mehmood S, Rashid U. Surveillance report on typhoid fever epidemiology and risk factor assessment in district Gujrat, Punjab, Pakistan. Biomedical Research 2017; 28: 6921-6.
  4. Singhal L. Post transfusion unilateral breast abscess caused by salmonella paratyphi A. Ijppr. Human 2021; 21(1): 454-9.
  5. Saad NJ, Lynch VD, Antillón M, Yang C, Crump JA, Pitzer VE. Seasonal dynamics of typhoid and paratyphoid fever. Sci Rep 2018; 8(1): 6870. doi: 10.1038/s41598-018-25234-w PMID: 29720736
  6. El-Sayed A, Kamel M. Climatic changes and their role in emergence and re-emergence of diseases. Environ Sci Pollut Res Int 2020; 27(18): 22336-52. doi: 10.1007/s11356-020-08896-w PMID: 32347486
  7. Agrawal S, Yadav VS, Srivastava A, Kapil A, Dhawan B. Breast abscess due to Salmonella paratyphi A: Case reports with review of literature. Intractable Rare Dis Res 2018; 7(2): 130-3. doi: 10.5582/irdr.2018.01031 PMID: 29862156
  8. Bhandari J, Thada PK, DeVos E. Typhoid Fever 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557513/
  9. Hannan A, Butt T, Islam SN. First quinolone resistant typhoid Salmonella. Pak Armed Forces Med J 1993; 44(1): 27-30.
  10. Saha SK, Talukder SY, Islam M, Saha S. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr Infect Dis J 1999; 18(4): 387. doi: 10.1097/00006454-199904000-00018 PMID: 10223698
  11. Miller SI, Peuges DA. Salmonella including Salmonella typhi. In: Mandel GL, Raphael D, Eds. Principles and practice of infectious diseases. (5th ed.). Chruchill Livingstone 2000; pp. 2345-63.
  12. Pavelquesi SLS, de Oliveira Ferreira ACA, Rodrigues ARM, de Souza Silva CM, Orsi DC, da Silva ICR. Presence of tetracycline and sulfonamide resistance genes in salmonella spp.: Literature review. Antibiotics 2021; 10(11): 1314. doi: 10.3390/antibiotics10111314 PMID: 34827252
  13. Kaurthe J. Increasing antimicrobial resistance and narrowing therapeutics in typhoidal salmonellae. J Clin Diagn Res 2013; 7(3): 576-9. PMID: 23634429
  14. Britto CD, Wong VK, Dougan G, Pollard AJ. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis 2018; 12(10): e0006779. doi: 10.1371/journal.pntd.0006779 PMID: 30307935
  15. Butler T, Rumans L, Arnold K. Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol-resistant strains of Salmonella typhi to treatment with trimethoprim-sulfamethoxazole. Clin Infect Dis 1982; 4(2): 551-61. doi: 10.1093/clinids/4.2.551 PMID: 6981171
  16. Cooles P. Adjuvant steroids and relapse of typhoid fever. J Trop Med Hyg 1986; 89(5): 229-31. PMID: 3795323
  17. Garcia JA, Damian RF. Typhoid fever. In: Rakel RE, Edward TB, Eds. Conn’s Current Therapy. (53rd ed.). W.B Saunders Co 2001; pp. 167-8.
  18. Umasankar S, Wall RA, Berger J. A case of ciprofloxacin-resistant typhoid fever. Commun Dis Rep CDR Rev 1992; 2(12): R139-40. PMID: 1284936
  19. Chiou CS, Lauderdale TL, Phung DC, et al. Antimicrobial resistance in salmonella enterica serovar typhi isolates from Bangladesh, Indonesia, Taiwan, and Vietnam. Antimicrob Agents Chemother 2014; 58(11): 6501-7. doi: 10.1128/AAC.03608-14 PMID: 25136011
  20. WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed 2017. Available from: http://www. who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/ Last accessed on 2017 Mar 08.
  21. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002; 8(4): 281-9. doi: 10.1089/10766290260469543 PMID: 12523625
  22. Singhal L, Gupta V, Gautam V, Kour I. XDR salmonella typhi warrants vaccine use in asian pacific region: Prevention is still better than cure. Asia Pac J Public Health 2023; 35(6-7): 463-4. doi: 10.1177/10105395231199159 PMID: 37665258
  23. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta Proteins Proteomics 2009; 1794(5): 769-81. doi: 10.1016/j.bbapap.2008.10.004
  24. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin Microbiol Rev 2009; 22(4): 664-89. doi: 10.1128/CMR.00016-09 PMID: 19822894
  25. Hooper DC, Jacoby GA. Mechanisms of drug resistance: Quinolone resistance. Ann N Y Acad Sci 2015; 1354(1): 12-31. doi: 10.1111/nyas.12830 PMID: 26190223
  26. Patel JB, Cockerill F III, Alder J, Bradford P, Eliopoulos G, Hardy D. CLSI. Performance standards for antimicrobial susceptibility testing.
  27. Gupta V, Pal K, Bhagat A, Goel A, Chander J. Quinolone susceptibility in salmonella isolates based on minimum inhibitory concentration determination. J Lab Physicians 2020; 12(4): 263-7. doi: 10.1055/s-0040-1721163 PMID: 33390675
  28. Veeraraghavan B, Anandan S, Sethuvel DP, Ragupathi NK. Pefloxacin as a surrogate marker for fluoroquinolone susceptibility for Salmonella Typhi: Problems and prospects. J Clin Diagn Res 2016; 10(8): DL01-2. doi: 10.7860/JCDR/2016/17022.8306 PMID: 27656439
  29. Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 2011; 9(6): 711-25. doi: 10.1586/eri.11.47 PMID: 21692675
  30. Samajpati S, Pragasam AK, Mandal S, Balaji V, Dutta S. Emergence of ceftriaxone resistant salmonella enterica serovar typhi in eastern India. Infect Genet Evol 2021; 96: 105093. doi: 10.1016/j.meegid.2021.105093 PMID: 34592414
  31. Eguale T, Gebreyes WA, Asrat D, Alemayehu H, Gunn JS, Engidawork E. Non-typhoidal Salmonella serotypes, antimicrobial resistance and co-infection with parasites among patients with diarrhea and other gastrointestinal complaints in Addis Ababa, Ethiopia. BMC Infect Dis 2015; 15(1): 497. doi: 10.1186/s12879-015-1235-y PMID: 26537951
  32. Mushtaq MA. What after ciprofloxacin and ceftriaxone in treatment of Salmonella typhi. Pak J Med Sci 2006; 22(1): 51.
  33. Al Naiemi N, Zwart B, Rijnsburger MC, et al. Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J Clin Microbiol 2008; 46(8): 2794-5. doi: 10.1128/JCM.00676-08 PMID: 18550740
  34. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008; 4.
  35. Nizamuddin S, Ching C, Kamal R, Zaman MH, Sultan F. Continued outbreak of ceftriaxone-resistant Salmonella enterica serotype Typhi across Pakistan and assessment of knowledge and practices among healthcare workers. Am J Trop Med Hyg 2021; 104(4): 1265-70. doi: 10.4269/ajtmh.20-0783 PMID: 33534746
  36. Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. MBio 2018; 9(1): e00105-18. doi: 10.1128/mBio.00105-18 PMID: 29463654
  37. González-López JJ, Piedra-Carrasco N, Salvador F, et al. ESBL-producing Salmonella enterica serovar Typhi in traveler returning from Guatemala to Spain. Emerg Infect Dis 2014; 20(11): 1918-20. doi: 10.3201/eid2011.140525 PMID: 25340972
  38. Qamar FN, Azmatullah A, Kazi AM, Khan E, Zaidi AKM. A three-year review of antimicrobial resistance of salmonella enterica serovars typhi and paratyphi A in Pakistan. J Infect Dev Ctries 2014; 8(8): 981-6. doi: 10.3855/jidc.3817 PMID: 25116662
  39. Patil N, Mule P. Sensitivity pattern of Salmonella typhi and paratyphi A isolates to chloramphenicol and other anti-typhoid drugs: an in vitro study. Infect Drug Resist 2019; 12: 3217-25. doi: 10.2147/IDR.S204618 PMID: 31686872
  40. Ramesh U, Das S, Balasubramanian A. Re-emergence of chloramphenicol-susceptible Salmonella Typhi and Paratyphi A strains in India. Indian J Med Microbiol 2016; 34(2): 262-3. doi: 10.4103/0255-0857.180393 PMID: 27080799
  41. Chand HJ, Rijal KR, Neupane B, Sharma VK, Jha B. Re-emergence of susceptibility to conventional first line drugs in Salmonella isolates from enteric fever patients in Nepal. J Infect Dev Ctries 2014; 8(11): 1483-7. doi: 10.3855/jidc.4228 PMID: 25390062
  42. Joshi S. Antibiogram of S. enterica serovar Typhi and S. enterica serovar Paratyphi A: A multi-centre study from India. WHO South-East Asia J Public Health 2012; 1(2): 182-8. doi: 10.4103/2224-3151.206930 PMID: 28612793
  43. Krishnan P, Stalin M, Balasubramanian S. Changing trends in antimicrobial resistance of Salmonella enterica serovar typhi and salmonella enterica serovar paratyphi A in Chennai. Indian J Pathol Microbiol 2009; 52(4): 505-8. doi: 10.4103/0377-4929.56140 PMID: 19805957
  44. Gupta V, Singhal L, Tejan N, Singla N, Kumar R, Chander J. Monitoring of antibiotic susceptibility pattern of blood isolates of Salmonella enterica var Typhi from a tertiary care hospital in North India. Eastern Journal Of Medical Sciences 2016; 1(1): 40-1. doi: 10.32677/EJMS.2016.v01.i01.010
  45. García C, Lejon V, Horna G, et al. Intermediate susceptibility to ciprofloxacin among Salmonella enterica serovar Typhi isolates in Lima, Peru. J Clin Microbiol 2014; 52(3): 968-70. doi: 10.1128/JCM.02663-13 PMID: 24371234
  46. Veeraraghavan B, Pragasam AK, Ray P, et al. Evaluation of antimicrobial susceptibility profile in Salmonella typhi and Salmonella paratyphi A: presenting the current scenario in India and strategy for future management. J Infect Dis 2021; 224 (Suppl. 5): S502-16. doi: 10.1093/infdis/jiab144 PMID: 35238369
  47. Gupta V, Singhal L, Goel A, Gupta M, Chander J. Risk factors and antimicrobial susceptibility pattern in patients with culture-positive typhoid. Natl Med J India 2018; 31(6): 380. doi: 10.4103/0970-258X.262899 PMID: 31397380
  48. Rai S, Jain S, Prasad KN, Ghoshal U, Dhole TN. Rationale of azithromycin prescribing practices for enteric fever in India. Indian J Med Microbiol 2012; 30(1): 30-3. doi: 10.4103/0255-0857.93017 PMID: 22361757
  49. Girish R, Kumar A, Khan S, Dinesh KR, Karim S. Revised ciprofloxacin breakpoints for salmonella: Is it time to write an obituary? J Clin Diagn Res 2013; 7(11): 2467-9. PMID: 24392374
  50. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52(3): 209-13. doi: 10.1016/j.diagmicrobio.2005.06.010 PMID: 16105566
  51. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007; 45(7): 2173-9. doi: 10.1128/JCM.02351-06 PMID: 17494717
  52. Capoor M, Nair D. Quinolone and cephalosporin resistance in enteric fever. J Glob Infect Dis 2010; 2(3): 258-62. doi: 10.4103/0974-777X.68529 PMID: 20927288
  53. Eykyn S, Williams H. Treatment of multiresistant Salmonella typhi with oral ciprofloxacin. Lancet 1987; 330(8572): 1407-8. doi: 10.1016/S0140-6736(87)91308-0 PMID: 2891000
  54. CLSI M100-S24: Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement 2014; M100-S24.
  55. Tao L, Foster P, Russo C, Cassat JE, Humphries RM. The brief case: Invasive ceftriaxone-resistant nontyphoidal salmonella and antimicrobial susceptibility testing considerations. J Clin Microbiol 2023; 61(5): e00750-22. doi: 10.1128/jcm.00750-22 PMID: 37219092
  56. Teklemariam AD, Al-Hindi RR, Albiheyri RS, et al. Human salmonellosis: A continuous global threat in the farm-to-fork food safety continuum. Foods 2023; 12(9): 1756. doi: 10.3390/foods12091756 PMID: 37174295
  57. Arii J, Tanabe Y, Miyake M, et al. Clinical and pathologic characteristics of nontyphoidal salmonella encephalopathy. Neurology 2002; 58(11): 1641-5. doi: 10.1212/WNL.58.11.1641 PMID: 12058092
  58. Khan M, Shamim S. Understanding the mechanism of antimicrobial resistance and pathogenesis of salmonella enterica serovar typhi. Microorganisms 2022; 10(10): 2006. doi: 10.3390/microorganisms10102006 PMID: 36296282
  59. Khanam F, Ross AG, McMillan NAJ, Qadri F. Toward typhoid fever elimination. Int J Infect Dis 2022; 119: 41-3. doi: 10.1016/j.ijid.2022.03.036 PMID: 35338009
  60. Akram J, Khan AS, Khan HA, et al. Extensively drug-resistant (XDR) typhoid: Evolution, prevention, and its management. BioMed Res Int 2020; 2020: 1-7. doi: 10.1155/2020/6432580 PMID: 32462008
  61. Cuypers WL, Jacobs J, Wong V, Klemm EJ, Deborggraeve S, Van Puyvelde S. Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing. Microb Genom 2018; 4(7): e000195. doi: 10.1099/mgen.0.000195 PMID: 29975627
  62. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 2015; 28(4): 901-37. doi: 10.1128/CMR.00002-15 PMID: 26180063
  63. Shin E, Park J, Jeong HJ, et al. Emerging high-level ciprofloxacin-resistant Salmonella enterica serovar typhi haplotype H58 in travelers returning to the Republic of Korea from India. PLoS Negl Trop Dis 2021; 15(3): e0009170. doi: 10.1371/journal.pntd.0009170 PMID: 33651791
  64. Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid-are conjugate vaccines arriving just in time? N Engl J Med 2018; 379(16): 1493-5. doi: 10.1056/NEJMp1803926 PMID: 30332569
  65. Marchello CS, Carr SD, Crump JA. A systematic review on antimicrobial resistance among Salmonella Typhi worldwide. Am J Trop Med Hyg 2020; 103(6): 2518-27. doi: 10.4269/ajtmh.20-0258 PMID: 32996447
  66. Jeon HJ, Pak GD, Im J, et al. Determining the best immunization strategy for protecting African children against invasive Salmonella disease. Clin Infect Dis 2018; 67(12): 1824-30. doi: 10.1093/cid/ciy386 PMID: 29746615
  67. Levine MM, Simon R. The gathering storm: Is untreatable typhoid fever on the way? MBio 2018; 9(2): e00482-18. doi: 10.1128/mBio.00482-18 PMID: 29559573
  68. Ejaz A, Khawaja A, Fatima K, Alavi N, Asif M. Frequency and antimicrobial resistance patterns of salmonella enterica isolates in a tertiary care setting. Pak J Med Health Sci 2022; 16(05): 11.
  69. Divyashree S, Nabarro LEB, Veeraraghavan B, Rupali P. Enteric fever in India: current scenario and future directions. Trop Med Int Health 2016; 21(10): 1255-62. doi: 10.1111/tmi.12762 PMID: 27495900
  70. India Go. National policy for containment of antimicrobial resistance India 2011.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024